Use of nitazoxanide as a new therapeutic option for persistent diarrhea: a pediatric perspective

References

• Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003;81: 197–204
   Google Scholar
• Avendano P, Matson DO, Long J, et al. Costs associated with office visits for diarrhea in infants and toddlers. Pediatr Infect Dis J 1993;12:897–902
   PubMed Web of Science ®Google Scholar
• Alinia: Investigators Brochure. 2002; Tampa, Florida, Romark Laboratories L.C.
   Google Scholar
• Scrimshaw NS, Murray EB. The acceptability of milk and milk products in populations with a high prevalence of lactose intolerance. Am J Clin Nutr 1988;48:1079–159
   PubMed Web of Science ®Google Scholar
• Cohen SA, Hendricks KM, Mathis RK, et al. Chronic nonspecific diarrhea: dietary relationships. Pediatrics 1979;64:402–7
   PubMed Web of Science ®Google Scholar
• Cohen SA, Hendricks KM, Eastham EJ, et al. Chronic nonspecific diarrhea. A complication of dietary fat restriction. Am J Dis Child 1979;133:490–2
   PubMedGoogle Scholar
• Guerrant RL, Van Gilder T, Steiner TS, et al. Practice guidelines for the management of infectious diarrhea. Clin Infect Dis 2001;32:331–51
   PubMed Web of Science ®Google Scholar
• Furness BW, Beach MJ, Roberts JM. Giardiasis surveillance – United States, 1992–1997. MMWR CDC Surveill Summ 2000;49: 1–13
   Google Scholar
• Guerrant RL. Cryptosporidiosis: an emerging, highly infectious threat. Emerg Infect Dis 1997;3:51–7
   PubMed Web of Science ®Google Scholar
• Lee SD, Surawicz CM. Infectious causes of chronic diarrhea. Gastroenterol Clin North Am 2001;30:679–92
   PubMed Web of Science ®Google Scholar
• Senay H, MacPherson D. Blastocystis hominis: epidemiology and natural history. J Infect Dis 1990;162:987–90
   PubMed Web of Science ®Google Scholar
• Doyle PW, Helgason MM, Mathias RG, et al. Epidemiology and pathogenicity of Blastocystis hominis. J Clin Microbiol 1990;28:116–21
   PubMed Web of Science ®Google Scholar
• Sun T, Katz S, Tanenbaum B, et al. Questionable clinical significance of Blastocystis hominis infection. Am J Gastroenterol 1989;84:1543–7
   PubMed Web of Science ®Google Scholar
• Massey V, Gregson DB, Chagla AH, et al. Clinical usefulness of components of the Triage immunoassay, enzyme immunoassay for toxins A and B, and cytotoxin B tissue culture assay for the diagnosis of Clostridium difficile diarrhea. Am J Clin Pathol 2003;119:45–9
   PubMed Web of Science ®Google Scholar
• Wilcox MH. Gastrointestinal disorders and the critically ill. Clostridium difficile infection and pseudomembranous colitis. Best Pract Res Clin Gastroenterol 2003;17:475–93
   PubMed Web of Science ®Google Scholar
• Jones JL, Lopez A, Wahlquist SP, et al. Survey of clinical laboratory practices for parasitic diseases. Clin Infect Dis 2004;38(Suppl 3):S198–202
   PubMedGoogle Scholar
• Turgeon DK, Fritsche TR. Laboratory approaches to infectious diarrhea. Gastroenterol Clin North Am 2001;30:693–707
   PubMed Web of Science ®Google Scholar
• Ortiz JJ, Ayoub A, Gargala G, et al. Randomized clinical study of nitazoxanide compared to metronidazole in the treatment of symptomatic giardiasis in children from Northern Peru. Aliment Pharmacol Ther 2001;15:1409–15
   PubMed Web of Science ®Google Scholar
• Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997;92:739–50
   PubMed Web of Science ®Google Scholar
• Menendez D, Bendesky A, Rojas E, et al. Role of P53 functionality in the genotoxicity of metronidazole and its hydroxy metabolite. Mutat Res 2002;501:57–67
   PubMed Web of Science ®Google Scholar
• Alinia (nitazoxanide): Prescribing information, July 2004; Tampa, Florida, Romark Laboratories L.C. Available from http://www. alinia.com/pdf/AliniaPI.pdf [Last accessed 13 Apr 2005]
   Google Scholar
• Dunne RL, Dunn LA, Upcroft P, et al. Drug resistance in the sexually transmitted protozoan Trichomonas vaginalis. Cell Res 2003;13:239–49
   PubMed Web of Science ®Google Scholar
• Abaza H, El-Zayadi AR, Kabil SM, et al. Nitazoxanide in the treatment of patients with intestinal protozoan and helminthic infections: a report on 546 patients in Egypt. Curr Ther Res Clin Exp 1998;59:116–21
   Web of Science ®Google Scholar
• Dubreuil L, Houcke I, Mouton Y, et al. In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms. Antimicrob Agents Chemother 1996;40:2266–70
   PubMed Web of Science ®Google Scholar
• Stockis A, Allemon AM, De Bruyn S, et al. Nitazoxanide pharmacokinetics and tolerability in man using single ascending oral doses. Int J Clin Pharmacol Ther 2002;40:213–20
   PubMed Web of Science ®Google Scholar
• Broekhuysen J, Stockis A, Lins RL, et al. Nitazoxanide: pharmacokinetics and metabolism in man. Int J Clin Pharmacol Ther 2000;38:387–94
   PubMed Web of Science ®Google Scholar
• Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Giardia intestinalis and Entamoeba histolytica or E. dispar: a randomized, double-blind, placebo-controlled study of nitazoxanide. J Infect Dis 2001;184:381–4
   Google Scholar
• Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 2002;360:1375–80
   PubMed Web of Science ®Google Scholar
• Ortiz JJ, Chegne NL, Gargala G, et al. Comparative clinical studies of nitazoxanide, albendazole and praziquantel in the treatment of ascariasis, trichuriasis and hymenolepiasis in children from Peru. Trans R Soc Trop Med Hyg 2002;96:1–4
   PubMedGoogle Scholar
• Rossignol JF, Hidalgo H, Feregrino M, et al. A ‘double-blind’ placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 1998;92:663–6
   PubMed Web of Science ®Google Scholar
• McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother 2000;44:2254–8
   PubMed Web of Science ®Google Scholar
• Megraud F, Occhialini A, Rossignol JF. Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole. Antimicrob Agents Chemother 1998;42:2836–40
   Google Scholar
• Sisson G, Goodwin A, Raudonikiene A, et al. Enzymes associated with reductive activation and action of nitazoxanide, nitrofurans, and metronidazole in Helicobacter pylori. Antimicrob Agents Chemother 2002;46:2116–23
   PubMed Web of Science ®Google Scholar